Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mirat Shah

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
The American Journal of Tropical Medicine and Hygiene|March 10, 2012
The economic value of a visceral leishmaniasis vaccine in Bihar state, IndiaBruce Y Lee, Kristina M Bacon, Mirat Shah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2025
Reply to: Decoding the End Points of Poly (ADP-ribose) Polymerase Inhibitor Trials in Ovarian CancerMirat Shah, Mallorie H Fiero, Joyce Cheng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 24, 2025
Totality of the Evidence: Optimizing Dosage Selection Strategies in OncologyLaura A Levit, Mirat Shah, Mark J Ratain, et al.
JCO Oncology Practice|April 28, 2020
Oncology Fellow-Led Quality Improvement Project to Improve Rates of Palliative Care Utilization in Patients With Advanced CancerRamy Sedhom, Arjun Gupta, Mirat Shah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2025
US Food and Drug Administration Approval Summary: Trastuzumab Deruxtecan for the Treatment of Adult Patients With Hormone Receptor-Positive, Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2-Low or Human Epidermal Growth Factor Receptor 2-Ultralow Breast CancerAsma Dilawari, Hui Zhang, Mirat Shah, et al.
JCO Oncology Practice|February 17, 2021
Developing Workshops to Enhance Hope Among Patients With Metastatic Breast Cancer and Oncologists: A Pilot StudyMirat Shah, Anna Ferguson, Phyllis Dvora Corn, et al.
The American Journal of Tropical Medicine and Hygiene|May 5, 2011
Economic value of dengue vaccine in ThailandBruce Y Lee, Diana L Connor, Sarah B Kitchen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2022
Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to PatientsJeanne Fourie Zirkelbach, Mirat Shah, Jonathon Vallejo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2022
FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast CancerMirat Shah, Christy L Osgood, Anup K Amatya, et al.
Journal of Neuro-Oncology|June 22, 2021
US Food and Drug Administration regulatory updates in neuro-oncologyGautam U Mehta, Amy K Barone, Diana Bradford, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
The American Journal of Tropical Medicine and Hygiene|March 10, 2012
The economic value of a visceral leishmaniasis vaccine in Bihar state, IndiaBruce Y Lee, Kristina M Bacon, Mirat Shah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2025
Reply to: Decoding the End Points of Poly (ADP-ribose) Polymerase Inhibitor Trials in Ovarian CancerMirat Shah, Mallorie H Fiero, Joyce Cheng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 24, 2025
Totality of the Evidence: Optimizing Dosage Selection Strategies in OncologyLaura A Levit, Mirat Shah, Mark J Ratain, et al.
JCO Oncology Practice|April 28, 2020
Oncology Fellow-Led Quality Improvement Project to Improve Rates of Palliative Care Utilization in Patients With Advanced CancerRamy Sedhom, Arjun Gupta, Mirat Shah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2025
US Food and Drug Administration Approval Summary: Trastuzumab Deruxtecan for the Treatment of Adult Patients With Hormone Receptor-Positive, Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2-Low or Human Epidermal Growth Factor Receptor 2-Ultralow Breast CancerAsma Dilawari, Hui Zhang, Mirat Shah, et al.
JCO Oncology Practice|February 17, 2021
Developing Workshops to Enhance Hope Among Patients With Metastatic Breast Cancer and Oncologists: A Pilot StudyMirat Shah, Anna Ferguson, Phyllis Dvora Corn, et al.
The American Journal of Tropical Medicine and Hygiene|May 5, 2011
Economic value of dengue vaccine in ThailandBruce Y Lee, Diana L Connor, Sarah B Kitchen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2022
Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to PatientsJeanne Fourie Zirkelbach, Mirat Shah, Jonathon Vallejo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2022
FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast CancerMirat Shah, Christy L Osgood, Anup K Amatya, et al.
Journal of Neuro-Oncology|June 22, 2021
US Food and Drug Administration regulatory updates in neuro-oncologyGautam U Mehta, Amy K Barone, Diana Bradford, et al.
Pageof 4